 |
 |

Myocardial Contractile Force in Hemorrhagic ShockTreatment With Phenoxybenzamine Hydrochloride, Metaproterenol Sulfate, or These Agents Combined
James R. Cook, MD;
Theordore R. Sherrod, MD, PhD;
Jack C. Cooley, MD
AMA Arch Surg. 1967;95(3):500-510.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
HEMORRHAGIC shock has been subject of concern to clinicians and has excited considerable interest among scores of investigators. The proper treatment of the patient in hemorrhagic shock constitutes a continuing discussion which has not been fully resolved. For many years, the accepted method of treating the severely hypotensive patient included a vasoconstrictor agent such as levarterenol or metaproteranol sulfate. These agents were effective in producing a marked elevation of blood pressure, but often did not result in the survival of the patient. In the mid-1950's such investigators as Nickerson1 and Lillehei2 suggested that vasodilating agents may offer a more physiologic approach to the treatment of patients in hemorrhagic shock. It was realized that effective tissue perfusion, rather than a normal blood pressure, was a more important factor in the survival of a shocked patient. This current study was conducted to evaluate myocardial performance when induced hemorrhagic shock is
. . . [Full Text PDF of this Article]
Author Affiliations
Chicago; Urbana, Ill
From the Department of Pharmacology, University of Illinois College of Medicine, Chicago (Drs. Cook and Sherrod), and the Division of Surgery, Carle Clinic and Hospital, Urbana, Ill (Dr. Cooley). Doctor Cook is now at the Gargos Hospital, Balboa Heights, Panama Canal Zone.
Footnotes
Submitted for publication Feb 25 1967.
Read before the 24th annual meeting of the Central Surgical Association, Pittsburgh, Feb 25, 1967.
Reprint requests to 901 S Wolcott St, Chicago 60612 (Dr. Sherrod).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|